A single-centre, placebo-controlled, double-blinded, randomized, cross-over study of Iloprost in patients with Eisenmenger syndrome
H. Nashat (London, United Kingdom), C. Harries (London, United Kingdom), L. Parfitt (London, United Kingdom), E. Shaw (London, United Kingdom), A. Kempny (London, United Kingdom), L. Price (London, United Kingdom), M. Gatzoulis (London, United Kingdom), K. Dimopoulos (London, United Kingdom), S. Wort (London, United Kingdom)
Source: International Congress 2018 – Pulmonary hypertension: therapy
Session: Pulmonary hypertension: therapy
Session type: Thematic Poster
Number: 3046
Disease area: Pulmonary vascular diseases
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
H. Nashat (London, United Kingdom), C. Harries (London, United Kingdom), L. Parfitt (London, United Kingdom), E. Shaw (London, United Kingdom), A. Kempny (London, United Kingdom), L. Price (London, United Kingdom), M. Gatzoulis (London, United Kingdom), K. Dimopoulos (London, United Kingdom), S. Wort (London, United Kingdom). A single-centre, placebo-controlled, double-blinded, randomized, cross-over study of Iloprost in patients with Eisenmenger syndrome. 3046
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you: